Reported Earlier, Zai Lab Announced New Data From A Preclinical Study Of ZL-1503, Demonstrating That The Company's Internally Developed IL-13/IL-31Rα Bispecific Antibody May Lead To Sustained Suppression Of Intense Pruritus And Inflammation Caused By Atopic Diseases